AS-23

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameAS-23

Drug Alias NameAS-23

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAceragen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAceragen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A